CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics is poised for significant growth, particularly with the anticipated acceleration in sales projected for 2026, driven by an expanded patient funnel and a nearly three-fold increase in infusion initiations. The potential of their gene editing program, CTX320, which has demonstrated up to 50% editing efficiency, along with the follow-on program CTX321, highlights the company's commitment to advancing innovative therapeutic solutions in genetically defined diseases. Furthermore, strong market demand for Casgevy, coupled with robust reimbursement prospects, underscores a positive outlook for the company's revenue generation across multiple high-total addressable market indications.

CRISPR Therapeutics faces significant risks related to potential regulatory hurdles that could negatively affect projections and market expectations, particularly if new drugs do not secure approval, leading to inevitable downward revisions in the company's financial outlook. Furthermore, the bear case projections suggest that if sales of Casgevy do not accelerate or if early-stage programs are discontinued, the stock could face a roughly 30% downside compared to base case assumptions. Additionally, the anticipated revenue growth of Casgevy, estimated at over $100 million in 2025, may be overly optimistic given the lowered expectation of uptake among eligible patients, projected to only reach 10% by 2035, which highlights a lack of robust commercial momentum.